Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $31.52, but opened at $35.28. Nanobiotix shares last traded at $35.1840, with a volume of 22,924 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Thursday. Guggenheim upped their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Stock Performance

The firm has a 50 day moving average price of $25.18 and a 200-day moving average price of $21.18.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. bought a new stake in shares of Nanobiotix during the third quarter worth approximately $101,000. Marshall Wace LLP acquired a new position in Nanobiotix in the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $390,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.